51 results about "BINAP" patented technology

The invention relates to a method for preparing L-carnitine by asymmetric catalytic hydrogenation reduction. Alkyl 4-chloroacetoacetate is used as a raw material, [RuCl(cymene)(S-BINAP)]Cl[chloro[(S)-(-)-2,2'-di(diphenylphosphine)-1,1'-binaphthyl](p-cymene)ruthenium chloride(II))] is used as a catalyst, and amination and hydrolysis reaction are carried out to obtain the L-carnitine product. The amination reaction does not need any solvent or virulent cyanide. The chemical purity of the L-carnitine product is higher than 97%, and the specific rotation [alpha]20D is -29 -32. The invention has the advantages of high reaction speed, stable catalytic system, low pressure required by the reaction process, high conversion rate, no need of solvent in the amination reaction, and is convenient to operate, thereby lowering the cost, reducing the environmental pollution and being convenient for large-scale production.

The invention discloses a preparation method of a multiphase asymmetric catalyst and belongs to the field of synthesis and application of functional materials. The catalyst is prepared from a metal component and a support. A preparation method of the catalyst support comprises the step as follows: a chiral bidentate phosphine ligand BINAP (5, 5'-divinyl-BIANP) containing vinyl is auto-polymerizedor is co-polymerized with other vinyl monomers with high steric hindrance; the metal component in the multiphase catalyst is Rh element. The periphery of the chiral phosphine ligand in a polymer skeleton is modified with other groups, a chiral pocket shown in the description is formed, so that catalytic performance of the multiphase catalyst in asymmetric hydroformylation can be improved, and enantio-selectivity of a product of the catalyst is increased by about 70% as compared with that of a homogeneous catalyst.

A low-cost, feasible and modular method for the preparation of new, highly selective "catalytic membranes" and their use in various types of reactors is disclosed. The membranes are versatile and reusable with negligible catalyst leaching, especially in the asymmetric hydrogenation of substituted α,β-unsaturated acids or esters. The membrane comprises a hybrid inorganic / polymer carrier material (i) and a molecular catalyst (ii) immobilized on the hybrid inorganic / polymer carrier material (i), wherein -(i) consists of an inorganic compound and an organic The hybrid inorganic / macromolecular compound composed of polymer chemical combination; -The inorganic compound is at least one selected from silicic acid compound, tungstic acid compound, molybdic acid compound and stannic acid compound; -The organic polymer Has a hydroxyl group, preferably polyvinyl alcohol (PVA); -(ii) is a pre-formed metal catalyst comprising at least one selected from Ru, Rh, Pd, Ir, Ni, Pt, Au A transition metal and at least one chiral ligand selected from phosphinos, aminos and / or amino-phosphines, preferably DIOP, BINAP monophosphorus or TMBTP.

The invention relates to a synthesis method of a drug for treating leukemia. The synthesis method comprises that 1, a compound 3-methyl-3-oxetanemethanol and sodium metal undergo a reaction to produce 3-sodium methoxide-3-methyl-3-oxetane, 2, 4-amino-3-nitrochlorobenzene is added into the product obtained by the step 1 so that reddish-orange solids (A1) are obtained, a compound 8-benzyloxyquinolin-2-chlorine and A1 undergo a reaction to produce orange solids A2, 3, the compounds A2, 13g of palladium / carbon and formic acid undergo a reaction, formamidine acetate is added into the reaction product, and the mixture is subjected to reflux and drying so that white-like (or yellow) solids A3 are obtained, and 4, the compounds A3 and benzenesulfonyl chloride undergo a reaction, the product is dried to form maize-yellow solids A4, BINAP, A4, tert-butyl piperidin-4-yl-carbamate and potassium carbonate undergo a reaction, the reaction product is dried to form A5, and the A5 is refined through the step 5 so that a pure product is obtained. In the steps 1 and 2, a one-pot method is used.

The invention belongs to the field of medicine synthesis and particularly provides a preparation method for Sitagliptin. According to the method, a cheap metal ruthenium complex and cheap R-BINAP serve as ligands, and the asymmetric hydrogenation reduction of an enamine intermediate is catalyzed, so that R-configuration Sitagliptin can be obtained in a high-selectivity manner; and the reaction time is short, and both the yield of reduction and the ee value of the product are relatively high, so that the method is applicable to industrialized amplified production.